Aprea Therapeutics, Inc. (NASDAQ:APRE) Short Interest Update

Aprea Therapeutics, Inc. (NASDAQ:APRE) saw a significant decline in short interest in the month of December. As of December 15th, there was short interest totaling 34,578 shares, a decline of 41.3% from the November 30th total of 58,925 shares. Based on an average daily volume of 100,933 shares, the short-interest ratio is presently 0.3 days. Currently, 0.6% of the shares of the company are sold short. Currently, 0.6% of the shares of the company are sold short. Based on an average daily volume of 100,933 shares, the short-interest ratio is presently 0.3 days.

Insider Activity at Aprea Therapeutics

In other Aprea Therapeutics news, Director Marc Duey purchased 21,459 shares of the company’s stock in a transaction that occurred on Wednesday, December 10th. The shares were bought at an average cost of $1.17 per share, for a total transaction of $25,107.03. Following the purchase, the director owned 256,155 shares of the company’s stock, valued at $299,701.35. This represents a 9.14% increase in their position. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Insiders own 13.63% of the company’s stock.

Aprea Therapeutics Price Performance

Shares of NASDAQ:APRE opened at $0.92 on Tuesday. The firm has a fifty day moving average price of $1.16 and a two-hundred day moving average price of $1.47. The company has a market cap of $6.43 million, a price-to-earnings ratio of -0.43 and a beta of 1.23. Aprea Therapeutics has a one year low of $0.90 and a one year high of $5.00.

Aprea Therapeutics (NASDAQ:APRE) last issued its quarterly earnings data on Wednesday, November 12th. The company reported ($0.47) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.11) by ($0.36). Aprea Therapeutics had a negative return on equity of 88.12% and a negative net margin of 2,666.46%.The business had revenue of $0.00 million during the quarter. Equities research analysts expect that Aprea Therapeutics will post -2.55 EPS for the current fiscal year.

Wall Street Analyst Weigh In

A number of equities research analysts have issued reports on APRE shares. Weiss Ratings reissued a “sell (e+)” rating on shares of Aprea Therapeutics in a report on Wednesday, October 8th. HC Wainwright decreased their price objective on Aprea Therapeutics from $20.00 to $5.00 and set a “buy” rating on the stock in a research note on Thursday, December 18th. Two investment analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat, the company currently has a consensus rating of “Hold” and an average target price of $8.00.

Aprea Therapeutics Company Profile

Aprea Therapeutics is a clinical‐stage biopharmaceutical company dedicated to developing targeted therapies that restore tumor suppressor function in cancers driven by TP53 mutations. The company’s lead investigational agent, eprenetapopt (APR-246), is designed to convert mutant p53 protein into a form that induces programmed cell death in malignant cells. Aprea’s research focuses on hematologic malignancies, including myelodysplastic syndromes (MDS) and acute myeloid leukemia (AML), as well as solid tumors harboring TP53 mutations.

Eprenetapopt has advanced through multiple clinical trials, including pivotal studies assessing its efficacy in combination with hypomethylating agents for patients with MDS.